Article
Genetic abnormalities in core binding factor acute myeloid leukemia.
[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Jan 2017
Ishikawa Yuichi
Abstract excerpt
Acute myeloid leukemia (AML) is a genetically heterogeneous disease, and its prognosis is stratified on the basis of chromosomal and genetic alterations. Core binding factor (CBF) leukemia consists of AML with t (8;21) (p22;q22) and inv16 (q16q16) /t (16;16) (q16;q16) and is included in AML with recurrent genetic abnormality according to WHO classification. Although CBF-AML is categorized as favorable-risk AML,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
